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A B S T R A C T
Pharmacogenomic tests used to guide clinical treatment for major depressive disorder (MDD) must be thor-
oughly validated. One important assessment of validity is the ability to predict medication blood levels, which
reflect altered metabolism. Historically, the metabolic impact of individual genes has been evaluated; however,
we now know that multiple genes are often involved in medication metabolism. Here, we evaluated the ability of
individual pharmacokinetic genes (CYP2C19, CYP2D6, CYP3A4) and a combinatorial pharmacogenomic test
(GeneSight Psychotropic®; weighted assessment of all three genes) to predict citalopram/escitalopram blood
levels in patients with MDD. Patients from the Genomics Used to Improve DEpression Decisions (GUIDED) trial
who were taking citalopram/escitalopram at screening and had available blood level data were included
(N=191). In multivariate analysis of the individual genes and combinatorial pharmacogenomic test separately
(adjusted for age, smoking status), the F statistic for the combinatorial pharmacogenomic test was 1.7 to 2.9-
times higher than the individual genes, showing that it explained more variance in citalopram/escitalopram
blood levels. In multivariate analysis of the individual genes and combinatorial pharmacogenomic test together,
only the combinatorial pharmacogenomic test remained significant. Overall, this demonstrates that the com-
binatorial pharmacogenomic test was a superior predictor of citalopram/escitalopram blood levels compared to
individual genes.
1. Introduction
The clinical use of pharmacogenomics to guide psychotropic med-
ication selection for patients with major depressive disorder (MDD) has
increased, which is at least partially attributable to growing concern
about the low success rate of standard approaches to treatment
selection. Fewer than 40% of patients experience remission after their
first medication trial, with rates decreasing further with subsequent
medication trials (Rush et al., 2006; Thase et al., 2005). The use of
pharmacogenomic testing to identify gene-drug interactions that may
contribute to medication failures offers the opportunity to make data-
driven decisions to avoid medications that are unlikely to be safe and/
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or effective for an individual patient.
The cytochrome P450 2C19 (CYP2C19) gene was among the first
included in pharmacogenomic testing based on the demonstrated in-
volvement of the CYP2C19 enzyme in the metabolism of medications
across many therapeutic areas (Scott et al., 2012; Whirl-Carrillo et al.,
2012). CYP2C19 metabolizes about 30% of the most commonly pre-
scribed psychotropic medications, including more than 60% of anti-
depressants, making it an important component of pharmacogenomic
testing in MDD (Nassan et al., 2016). However, it is now well known
that most drugs are impacted by multiple metabolic pathways
(McDonnell and Dang, 2013). Thus, it became important to expand
pharmacogenomic testing to assess additional genes to more compre-
hensively and accurately characterize gene-drug interactions for med-
ications that are metabolized by additional enzymes independently or
in combination with CYP2C19.
There are ongoing efforts to help “translate” genetic information
into clinical recommendations to improve prescribing practices for
patients with MDD. However, there is no current global consensus and
recommendations vary between professional society guidelines, gov-
ernment agencies, and testing laboratories. This is exemplified by the
selective serotonin reuptake inhibitor (SSRI) citalopram, which is often
the first line of treatment for depression (Gelenberg et al., 1993 (Re-
vised 2015, Reafirmed 2015); Rush et al., 2006). Although citalopram is
primarily metabolized by CYP2C19, the CYP2D6 and CYP3A4 enzymes
are also involved (Sangkuhl et al., 2011). The Clinical Pharmacoge-
netics Implementation Consortium (CPIC) and FDA make therapeutic
recommendations for citalopram based on CYP2C19 metabolizer status.
However, CPIC makes clinical recommendations for ultrarapid, rapid,
and poor metabolizers (Hicks et al., 2015) while the FDA label only
includes a recommended dose change for poor metabolizers (U.S. Food
& Drug Administration, 2019; U.S. Food and Drug Administration,
2017). Many clinical testing laboratories make recommendations based
on CYP2C19, CYP2D6, and/or CYP3A4; however, some laboratories
provide individual phenotype information for each gene
(Brennan et al., 2015; Pérez et al., 2017) while others provide a com-
bined phenotype that factors in the combined impact of genetic varia-
tions in multiple genes (Hall-Flavin et al., 2012). Phenotype assign-
ments of individual SNPs for all three genes also vary between testing
laboratories (Bousman and Dunlop, 2018) and, in some cases, with
CPIC guidelines.
This example of citalopram highlights three key considerations for
the clinical utilization of pharmacogenomic testing: 1) what genes
should be tested, 2) what genotypes and phenotypes should be used for
each gene, and 3) how to interpret multiple genetic variations across
multiple genes that are relevant for a single medication. The last point
is particularly important for medications like citalopram that have
complex metabolic pathways (Sangkuhl et al., 2011). Alteration in one
metabolic pathway could be compensated for or amplified by an al-
teration in another pathway. In addition, secondary metabolic path-
ways are often less efficient, and the combined effect of multiple genetic
variations may not be equal. Therefore, the interpretation of multiple
genetic variations and genes that impact a single medication must ac-
count for the combined, weighted impact of all relevant phenotypes.
Given the number of critical factors that must be considered in
pharmacogenomic testing, each test should be thoroughly validated to
be appropriate for clinical use. An important assessment of the validity
for any pharmacogenomic test is the ability to accurately predict
medication blood levels, which reflects the ability to predict changes in
metabolism based on the tested genes and assigned phenotypes (in-
dividual and combined). In this study, we assessed the ability to predict
medication blood levels using individual genes compared to a combi-
natorial pharmacogenomic test (GeneSight® Psychotropic) in patients
with MDD taking citalopram or escitalopram as part of the Genomics
Used to Improve DEpression Decisions (GUIDED) trial (Greden et al.,
2019). This included an evaluation of individual gene phenotype calls
as made by the testing laboratory and by CPIC recommendations as well
as the combined phenotype from the combinatorial pharmacogenomic
test.
2. Methods
2.1. Cohort
GUIDED was a large, patient- and rater-blinded, randomized, con-
trolled trial comparing the impact of treatment selection guided by
combinatorial pharmacogenomic testing (guided-care) versus treatment
as usual on outcomes of patients with MDD. Patients were included if
they had a diagnosis of MDD, a score of ≥11 on the self-rated and
clinician-rated 16-item Quick Inventory of Depressive Symptomatology
Scale, and at least one failed psychotropic medication trial within the
current depressive episode (defined as inadequate efficacy after 6 weeks
of treatment, discontinuation due to adverse events, or intolerability). A
detailed description of the study design has been previously published
(Greden et al., 2019). The trial was approved by the Copernicus Group
independent review board (INC1-14-012) and all patients provided
written informed consent.
We evaluated all patients who met eligibility criteria at the
screening visit, were identified as taking citalopram or escitalopram at
the time of the screening visit (either in their medical history at
screening or by indicating that citalopram or escitalopram were being
dropped at the baseline visit), specified their citalopram or escitalo-
pram dose, and had provided a blood sample. Patients were excluded
from analysis if their citalopram or escitalopram blood levels were
below the lower level of quantification. Citalopram and escitalopram
were selected for this analysis because, combined, they were the most
common antidepressants being taken at baseline for which blood levels
were obtainable in the GUIDED trial.
To examine the generalizability of the phenotype combinations
identified in the GUIDED trial sample, we examined the phenotypes in a
large clinical population. This sample consisted of a sequential series of
patients who underwent combinatorial pharmacogenomic testing or-
dered by their treating clinician in the course of their clinical care. This
included patients who received clinical testing between April 2014 to
October 2019. Only patients who provided consent for their informa-
tion to be used for research purposes were included.
2.2. Combinatorial Pharmacogenomic Testing
All patients were tested with the GeneSight Psychotropic test
(Assurex Health Inc., Mason, OH) as previously described
(Jablonski et al., 2018). This included an evaluation of the genotypes of
59 alleles and variants across 8 genes (CYP1A2: -3860G>A,
-2467T>delT, -739T>G, -729C>T, -163C>A, 125C>G, 558C>A,
2116G>A, 2473G>A, 2499A>T, 3497G>A, 3533G>A, 5090C>T,
5166G>A, 5347C>T; CYP2C9: *1, *2, *3, *4, *5, *6; CYP2C19: *1, *2,
*3, *4, *5, *6, *7, *8, *17; CYP3A4: *1, *13, *15A, *22; CYP2B6: *1, *4,
*6, *9; CYP2D6: *1, *2, *2A, *3, *4, *5 (gene deletion), *6, *7, *8, *9,
*10, *11, *12, *14, *15, *17, *41, gene duplication; HTR2A: -1438 G
>A; SLC6A4: L, S).
For each medication, a combined phenotype was assigned based on
a weighed algorithmic assessment of individual phenotypes in genes
involved in the pharmacokinetics (metabolism) or pharmacodynamics
(mechanism of action) of that medication. The relative contribution of
each enzyme involved in the metabolism of the medication was
weighted. These pharmacokinetic weights were combined with phar-
macodynamic weights in an algorithm that describes the additive or
offsetting effects that each enzyme has on medication metabolism, as
well as the impact of genetic variation on efficacy or side effects.
The resultant combined phenotype for each medication was used to
categorize the medication according to the predicted level of gene-drug
interactions in three categories: ‘use as directed’ (no gene-drug inter-
actions), ‘use with caution’ (moderate gene-drug interactions), or ‘use
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with increased caution and with more frequent monitoring’ (significant
gene-drug interactions). The test report included recommendations or
highlighted relevant considerations for each medication based on the
type and severity of predicted gene-drug interactions. This may have
included recommendations to increase dose, decrease dose, considera-
tion of reduced efficacy or increased side-effect risk, or that the medi-
cation is contraindicated. For example, citalopram would be in the
“significant gene-drug interaction” report category with a re-
commendation to decrease the dose for an individual who is a CYP2C19
intermediate metabolizer, CYP2D6 poor metabolizer, and CYP3A4
normal metabolizer due to the combined weights of the pharmacoki-
netic genes. In comparison, the phenotype based on CYP2C19 alone
would not indicate a recommendation to change the starting dose
(Hicks et al., 2015).
2.3. Individual Gene Phenotype Assignments
CPIC guidelines include recommendations for assigning CYP2C19
(Hicks et al., 2015) and CYP2D6 (Caudle et al., 2019) phenotypes for
SSRIs. This includes assignments as ultrarapid, rapid (CYP2C19 only),
normal (extensive), intermediate, or poor metabolizers based on the
number of increased, normal, decreased, or no function alleles (Sup-
plemental Table 1) (Caudle et al., 2019; Hicks et al., 2015). In brief,
individuals with increased function alleles (alone or in combination
with normal function alleles) or duplications of functional alleles were
defined as ultrarapid metabolizers. Individuals with only no function
alleles were defined as poor metabolizers. Individuals were defined as
normal, intermediate, or rapid metabolizers based on a combination of
normal function, decreased function, increased function, and/or no
function alleles. Of note is that CPIC guidelines provide recommenda-
tions for CYP2D6 phenotypes for SSRIs but do not include dosing re-
commendations for citalopram (Hicks et al., 2015).
As part of the combinatorial pharmacogenomic test performed in
the GUIDED trial, phenotypes were assigned for each individual gene.
For CYP2C19 and CYP2D6, these phenotypes differed from CPIC
guidelines for SSRIs for some allele interpretations (Supplemental
Table 1). Specifically, CPIC classified individuals with CYP2C19 *2/
*17 as intermediate metabolizers and individuals with CYP2C19 *1/
*17 as rapid metabolizers (Hicks et al., 2015). The combinatorial
pharmacogenomic test classified individuals with both of these geno-
types as normal metabolizers. In addition, the pharmacogenomic test
did not include a rapid metabolizer phenotype. For CYP2D6, the com-
binatorial pharmacogenomic test and CPIC differed in the definitions of
poor and ultrarapid metabolizers. Patients with two alleles that have at
least moderately decreased activity were called poor metabolizers for
the combinatorial pharmacogenomic test. This increased the number of
poor metabolizers compared to CPIC guidelines, which only included
carriers of two non-functional alleles (Caudle et al., 2019). In addition,
the combinatorial pharmacogenomic test included the CYP2D6*2A al-
lele as an increased function allele, which increased the number of
ultrarapid metabolizers beyond those with gene duplications.
2.4. Blood Concentrations
Citalopram (R/S-citalopram) and escitalopram (S-citalopram only)
blood concentrations were quantified using liquid chromatography
with tandem mass spectrometry (LC-MS/MS). The methodologies uti-
lized here could not distinguish between citalopram enantiomers.
However, the S-citalopram enantiomer is the active ingredient in both
citalopram and escitalopram and the concentration/dose ratio accounts
for dosing differences in citalopram and escitalopram treatment. As
such, it is unnecessary to distinguish enantiomers for this analysis.
Venous blood samples (3mL) were stored in EDTA blood vials (BD
Vacutainer® EDTA tubes, BD Diagnostics, Franklin Lakes, NJ, USA) and
were kept at -80 degrees Celsius until analysis. The LC-MS/MS system
utilized Sciex Triple Quadrupole 6500PLUS instrument (AB Sciex LP,
Ontario, Canada) coupled with two Shimadzu Nexera X2 LC-30AD
pumps (Shimadzu Scientific Instruments, Columbia, MD, USA), and a
CTC PAL-xt autosampler (CTC Analytics AG, Zwingen, Switzerland).
The drug concentrations from 10μL of lysed whole blood were de-
termined by Precera Bioscience, Inc. (Franklin, TN, USA). The lower
limit of quantification was 5ng/mL and the upper limit of quantification
was 1000ng/mL. Detection was performed by multiple reaction mon-
itoring (MRM) in the positive mode with the following m/z transition:
325.1 → 262.151. The time since last dose and concomitant medica-
tions were uncontrolled.
2.5. Statistical Analysis
Log-transformed concentration/dose ratios based on the dose at the
screening visit were used to account for the impact of dosing differences
between patients. The concentration/dose ratio also accounts for dosing
differences in citalopram and escitalopram treatment. As such, all
analyses were performed for the combined cohort of patients taking
citalopram or escitalopram (referred to as citalopram throughout).
Percent changes in the concentration/dose ratio were reported on a
non-log scale. The ability to predict citalopram concentration/dose
ratios was assessed for the combinatorial pharmacogenomic test ac-
cording to the level of gene-drug interactions and metabolic impact
based on only the relevant pharmacokinetic genes (CYP2C19, CYP2D6,
CYP3A4): significant gene-drug interaction with decreased metabolism,
moderate gene-drug interaction with decreased metabolism, no gene-
drug interaction, moderate gene-drug interaction with unknown me-
tabolic impact, moderate gene-drug interaction with increased meta-
bolism, significant gene-drug interaction with increased metabolism.
CYP2C19, CYP2D6, and CYP3A4 were also evaluated individually
based on phenotype: ultrarapid metabolizer, intermediate metabolizer,
normal metabolizer, poor metabolizer. Individual gene assessments for
CYP2C19 and CYP2D6 were performed separately using CPIC re-
commended phenotypes (Caudle et al., 2019; Hicks et al., 2015) and
phenotypes assigned during combinatorial pharmacogenomic testing.
Individual CYP2C19 genotypes were also evaluated when they differed
between CPIC recommendations and the combinatorial pharmacoge-
nomic test.
To test the association between genetic factors and drug metabo-
lism, ANCOVA tests with categorical genetic variables were used to
assess the relationship between log-transformed concentration/dose
ratios and genotypes, phenotypes, and gene-drug interactions from the
combinatorial pharmacogenomic test. To test the linear relationship
between recommendations from the pharmacogenomic test and from
CPIC with drug metabolism, ANCOVA tests with numerically trans-
formed phenotypes and gene-drug interactions were used to compare
the variability explained by the recommendations from CPIC and from
the combinatorial pharmacogenomic test as described in the
Supplemental Methods.
The relationship between citalopram log-transformed concentra-
tion/dose ratios and each of the single gene numeric scores were as-
sessed individually. Then they were assessed in a single ANCOVA with
the numeric score for the combinatorial pharmacogenomic test to show
the amount of unique variance explained by each variable; that is, ac-
counting for an overlap in recommendations for some patients. Age and
smoking status were included as covariates in all analyses. Pairwise
comparisons were not conducted for samples sizes of less than 5.
Statistical analyses were performed using R, version 3.4.4.
3. Results
3.1. Cohort
In the GUIDED trial, blood level and dose information were avail-
able for 96 patients taking citalopram and 95 patients taking escitalo-
pram. Although blood sample collections were not controlled for time
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of drug intake, there was a significant relationship between log-trans-
formed concentration and dose (r2=0.49, p<0.0001; Supplemental
Figure 1).
In the combined cohort (N=191), the mean age was 49.7 years,
72% of patients were female, and 95% of patients were non-Hispanic/
Latino (Table 1). Overall, 13% of patients had a history of smoking.
Smokers and non-smokers had significantly different citalopram blood
levels, with a 31% reduction in non-transformed blood levels in smo-
kers (p=0.008). There were no substantial differences in demographics
between patients taking citalopram or escitalopram (Table 1).
3.2. Validity of Individual Genes and Phenotypes
Fig. 1 shows the concentration/dose ratios for citalopram according
to phenotype calls for CYP2C19 made according to the combinatorial
pharmacogenomic test and according to CPIC guidelines. Log con-
centration/dose ratios for citalopram were significantly different across
all CYP2C19 phenotype classifications as defined by the pharmacoge-
nomic test (p=0.0007; Fig. 1A). Compared to CYP2C19 normal meta-
bolizers, CYP2C19 ultrarapid metabolizers had a 42% decrease in
concentration/dose ratios (p=0.04) and CYP2C19 intermediate meta-
bolizers had a 40% increase in concentration/dose ratios (p=0.001)
when the combinatorial pharmacogenomic test phenotype assignments
were used.
Log concentration/dose ratios for citalopram also were significantly
different across all CYP2C19 phenotype classifications as defined by
CPIC (p=0.004; Fig. 1B). CPIC-classified intermediate metabolizers had
a 29% increase in concentration/dose compared to CPIC CYP2C19
normal metabolizers (p=0.03). Patients with the CYP2C19*2/*17
genotype were classified as intermediate metabolizers based on CPIC
guidelines but were classified as normal metabolizers by the combina-
torial pharmacogenomic test. Concentration/dose ratios for these pa-
tients did not significantly differ from patients with the normal meta-
bolizer CYP2C19*1/*1 genotype (p=0.86; Supplemental Figure 2).
Additionally, there was no difference between concentration/dose ra-
tios for CPIC-classified rapid and normal metabolizers (p=0.34). This is
due to the fact that patients with the CYP2C19*1/*17 genotype were
considered rapid metabolizers according to CPIC guidelines and there
was no significant difference in concentration/dose ratios between
CYP2C19*1/*17 and CYP2C19 *1/*1 (p=0.33; Supplemental Figure
2).
CYP2D6 was significant when the phenotypes assigned by the
combinatorial pharmacogenomic test were used (p=0.01; Fig. 1C).
Similarly, CYP2D6 was significant when the phenotypes were assigned
using CPIC guidelines (p=0.002; Fig. 1D). This analysis utilized the
recently released updates to CPIC recommendations for CYP2D6 phe-
notyping (Caudle et al., 2019). In comparison, CYP2D6 was not
significant when the previous CPIC recommendations for CYP2D6
phenotypes were utilized (p=0.13; Supplemental Figure 3)
(Hicks et al., 2015). There was no difference between CYP3A4 normal
and intermediate metabolizers (p=0.51; Fig. 1E). There were no pa-
tients identified as CYP3A4 poor metabolizers.
3.3. Validity of Combinatorial Pharmacogenomic Test Compared to
Individual Genes
There were 17 unique combinations of CYP2C19, CYP2D6, and
CYP3A4 phenotypes in this cohort (Table 2). The most common com-
bination was normal metabolizer in all three genes (76/191, 39.8%). A
total of 94 (49.2%) patients were poor, intermediate, or ultrarapid
metabolizers in CYP2D6 and/or CYP3A4. The individual gene pheno-
types for CYP2C19, CYP2D6, and CYP3A4 were factored into the
combined phenotypes that informed the final report category and dose
recommendations. This is demonstrated in Fig. 2A, where the final
combinatorial pharmacogenomic report category is broken down by the
contributing phenotypes. Solid color bars in Fig. 2A indicate that the
final report category was based on an individual phenotype, where blue
and purple bars correspond to genes other than CYP2C19. Overall,
44.5% (85/191) of patients had a variation in only one gene, 75.3%
(64/85) of whom had a variation in a gene other than CYP2C19. For
example, all patients for whom citalopram was in the “moderate gene-
drug interaction with increased metabolism” report category were
CYP2D6 ultrarapid metabolizers. Bars with multiple colors in Fig. 2A
indicate that the final report category was informed by variations in
more than one gene. Overall, 15.7% (30/191) of patients had an al-
teration in multiple genes. For example, 56.2% (9/16) of patients for
whom citalopram was in the “significant gene-drug interaction with
decreased metabolism” report category were CYP2C19 intermediate
metabolizers and CYP2D6 poor metabolizers.
Citalopram log concentration/dose ratios were significantly dif-
ferent between report categories from the combinatorial pharmacoge-
nomic test (p=0.003; Fig. 2B). Citalopram was categorized as having
significant gene-drug interactions with increased metabolism using the
combinatorial pharmacogenomic test for 6 patients (3.1%). The con-
centration/dose ratios were 47% lower in these patients compared to
when citalopram had no gene-drug interaction (p=0.03). These pa-
tients were all CYP2C19 ultrarapid metabolizers. Citalopram was ca-
tegorized as having significant gene-drug interactions with decreased
metabolism using the combinatorial pharmacogenomic test for 16
(8.4%) patients. The concentration/dose ratios were 54% higher in
these patients compared to when citalopram was subject to no gene-
drug interactions (p=0.005; Fig. 2B). However, only 3 (19%) of these
patients were CYP2C19 poor metabolizers (Fig. 2A). The remaining 13
patients would not have been candidates for dose modification based on
CYP2C19 alone but were identified as having significant gene-drug
interactions with decreased metabolism based on the combination of
CYP2C19, CYP2D6, and CYP3A4 phenotypes (Supplemental Table 2).
Further evaluation of the individual phenotypes that contributed to
the final test report category in Fig. 2A demonstrates the frequency with
which the addition of CYP2D6 and CYP3A4 resulted in a different
combined phenotype compared to CYP2C19 alone. For example, 35
patients were CYP2C19 intermediate metabolizers, which is not asso-
ciated with a CPIC recommended dose modification (Hicks et al., 2015);
however, 11 of these patients (31.4%) were categorized as having sig-
nificant gene-drug interactions with decreased metabolism according to
the pharmacogenomic test, due to combined effects of CYP2C19,
CYP2D6, and CYP3A4. In this subset of patients, the concentration/dose
ratio was 59% higher than when citalopram had no gene-drug inter-
action (p=0.02).
Multivariate analysis adjusted for age and smoking status was per-
formed to evaluate the linear relationship between the pharmacoge-
nomic test and individual genes with citalopram metabolism. This
analysis showed that CYP2C19 alone was a significant predictor of
Table 1
Baseline Patient Demographics. Clinical and demographic characteristics for
patients taking citalopram or escitalopram at screening in the GUIDED trial.
Characteristic Citalopram
(N=96)
Escitalopram
(N=95)
Total
(N=191)
Age (years)
Mean (SD) 51 (13.4) 48.3 (14.4) 49.7 (14.0)
Min, Max 19, 73 18, 90 18, 90
Sex, n (%)
Female 69 (72%) 68 (72%) 137 (72%)
Male 27 (28%) 27 (28%) 54 (28%)
Ethnicity, n (%)
Hispanic or Latino 6 (6%) 3 (3%) 9 (5%)
Not Hispanic or
Latino
90 (94%) 92 (97%) 182 (95%)
Smoker, n (%)
Yes 12 (13%) 13 (14%) 25 (13%)
No 84 (88%) 82 (86%) 166 (87%)
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citalopram blood levels (Table 3). This was true when CYP2C19 phe-
notypes were made using CPIC guidelines (p=0.006) or the pharma-
cogenomic test phenotype assignments (p=0.01). An evaluation of
CYP2D6 alone showed that the gene was not significant when using
CPIC phenotyping (p=0.84); however, CYP2D6 was significant when
the pharmacogenomic test phenotype assignments were used (p=0.03;
Table 3). Analysis of the combinatorial pharmacogenomic test alone
showed that the test was a significant predictor of citalopram blood
levels (p=0.0003, Table 3). The F statistic for combinatorial pharma-
cogenomic testing was 1.7 to 2.9-times higher than for the individual
genes, showing that the combinatorial pharmacogenomic test explained
more variance in citalopram blood levels than the individual genes. The
relative improvement of combinatorial pharmacogenomic testing could
not be compared to CYP2D6 (CPIC-defined phenotypes) because the F
statistic for CYP2D6 was not significantly different from zero.
Multivariate analyses that incorporated the individual genes and the
combinatorial pharmacogenomic test were also performed. For both
CYP2C19 and CYP2D6, the individual genes were not significant in
multivariate analysis that included the pharmacogenomic test
(Table 4). This was true both when CPIC phenotypes were used and
when the pharmacogenomic test phenotype assignments were used.
Conversely, the combinatorial pharmacogenomic test remained highly
significant in multivariate analyses that included CYP2C19 and CYP2D6
(Table 4). This demonstrates that, even in the presence of individual
gene phenotypes, the combinatorial pharmacogenomic test explained
an additional, significant portion of the variance in concentration/dose
ratios relative to CYP2C19 or CYP2D6 alone, with substantially higher
predictive power than the individual genes.
3.4. Extrapolation to Clinical Testing Population
The distribution of phenotype combinations for CYP2C19, CYP2D6,
and CYP3A4 in this cohort was similar to the distribution observed in
the clinical testing population for the combinatorial pharmacogenomic
Fig. 1. Citalopram and Escitalopram Blood Levels According to Individual Gene Phenotypes from CPIC and the Combinatorial Pharmacogenomic Test.
Boxplots of the log-transformed concentration/dose ratios according to phenotype for CYP2C19, CYP2D6, and CYP3A4. The median (thick horizontal line), inter-
quartile range (box), plus/minus 1.5xinterquartile range (vertical lines) are shown, with outliers shown as individual dots. Phenotypes were evaluated based on the
assignments from the combinatorial pharmacogenomic test and using CPIC guidelines for SSRIs (only available for CYP2C19 and CYP2D6).
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test (Table 2). This indicates that the trends observed in the sub-set of
patients from the GUIDED trial are applicable to a broader clinical
population. When phenotypes that were observed here and in the
clinical population were considered, 70,486 patients in the clinical
testing population (6.9%) received clinically actionable pharmacoge-
nomic information related to reduced metabolism for citalopram.
Among these patients, 19,345 patients (1.9%) were CYP2C19 poor
metabolizers and would have received similar guidance based on CPIC
guidelines for citalopram (Hicks et al., 2015). However, the remaining
51,141 (5.0%) patients had a combined phenotype that resulted in
significant gene-drug interactions with reduced metabolism and would
not have received clinical guidance based on current CPIC guidelines
because they were not CYP2C19 poor metabolizers.
This increase in the proportion of patients identified as having
clinically actionable gene-drug interactions is largely due to the inclu-
sion of CYP2D6 and CYP3A4 into citalopram guidance as part of this
combinatorial pharmacogenomic test. For example, the most frequent
phenotype combination that resulted in a report category of “significant
gene-drug interaction with reduced metabolism” for citalopram was
CYP2C19 intermediate metabolizer, CYP2D6 poor metabolizer, and
CYP3A4 normal metabolizer. In the clinical testing population, 38.2%
(26,919/70,486) of patients for whom citalopram was in the “sig-
nificant gene-drug interaction with reduced metabolism” report cate-
gory had this phenotype combination (Table 2). For these patients, this
report classification is a direct reflection of the inclusion of CYP2D6
into citalopram guidance in the combinatorial pharmacogenomic test.
4. Discussion
The use of pharmacogenomics to personalize treatment may im-
prove treatment selection, and ultimately outcomes, for patients with
MDD. With the growing number and types of available pharmacoge-
nomic tests, it is important that tests be subjected to robust validation to
ensure appropriate clinical use. This is especially important in MDD,
where previous studies have shown that pharmacogenomic tests are
different from each other and must be evaluated separately
(Bousman and Dunlop, 2018). The utility of the combinatorial phar-
macogenomic test used here has been previously evaluated (Hall-
Flavin et al., 2013; Hall-Flavin et al., 2012; Winner et al., 2013), most
recently in the GUIDED trial (Greden et al., 2019). The test has also
been previously validated (Altar et al., 2015); however, a direct eva-
luation of the ability of the test to predict medication blood levels has
not been possible due to limited available data. Using data from the
GUIDED trial, we were able to validate the combinatorial pharmaco-
genomic test against citalopram and escitalopram blood levels.
An important consideration in pharmacogenomic testing is geno-
type and phenotype assignments, as this informs clinical re-
commendations for dose adjustments or whether a medication with a
different mechanism of action should be considered. In this study, the
concentration/dose ratios for citalopram and escitalopram were corre-
lated with the CYP2C19 phenotypes recommended by CPIC guidelines
and assigned by the combinatorial pharmacogenomic test. However,
there was no difference between CPIC rapid and normal metabolizers.
The genotypes that are classified differently between CPIC and the
combinatorial pharmacogenomic test (CYP2C19*2/*17 and
CYP2C19*1/*17) were not found to be a significant predictor of con-
centration/dose ratios. These data demonstrate that the CYP2C19
phenotype calls made by the combinatorial pharmacogenomic test are
better predictors of citalopram and escitalopram blood levels than
phenotype assignments from CPIC.
Additional considerations in pharmacogenomic testing include
which genes to test and the combined effect of relevant phenotypes for
each medication. The metabolic pathway for citalopram is largely
regulated by CYP2C19 and CPIC guidelines provide clinical re-
commendations for citalopram prescribing based on CYP2C19 pheno-
types alone (Hicks et al., 2015). However, CYP2D6 and CYP3A4 are
also involved in citalopram metabolism. Citalopram and escitalopram
blood levels were significantly different between the gene-drug inter-
action categories from the combinatorial pharmacogenomic test based
on the combined effect of CYP2C19, CYP2D6, and CYP3A4. Con-
sideration of CYP2C19 alone, as done by CPIC, would miss any relevant
contribution from these genes.
Although there are limited data available describing the relation-
ship between es/citalopram blood concentrations and medication effi-
cacy and tolerability, it is commonly implied by CPIC and others that a
50% change in expected blood concentration is clinically actionable.
For CYP2C19 poor metabolizers, there is an implied risk of adverse
events based on the significant increase in concentration relative to
normal metabolizers (Hicks et al., 2015). In addition, there is evidence
of es/citalopram dose-related QT prolongation and risk of arrythmia
with a 50% increase in blood levels (Funk and Bostwick, 2013). Based
on this direct or implied evidence, CPIC and FDA offer clinical guidance
for CYP2C19 poor metabolizers to reduce es/citalopram dose by 50%
(Hicks et al., 2015; U.S. Food & Drug Administration, 2019;
U.S. Food and Drug Administration, 2017). Furthermore, the significant
decrease in concentration for CYP2C19 ultrarapid metabolizers relative
Table 2
Phenotype Combinations in GUIDED and the Clinical Testing Population. Comparison of phenotypes from the combinatorial pharmacogenomic test in the subset of
patients from the GUIDED trial with information on citalopram or escitalopram blood levels and in the clinical testing population.
Phenotype GUIDED (N=191) Clinical Testing Population (N=1,014,267a)
CYP2C19 CYP2D6 CYP3A4 N % N %
normal normal normal 76 39.8% 391,245 38.6%
normal intermediate normal 35 18.3% 160,615 15.8%
intermediate normal normal 13 6.8% 105,559 10.4%
normal poor normal 13 6.8% 96,610 9.5%
normal ultrarapid normal 9 4.7% 48,374 4.8%
intermediate poor normal 9 4.7% 26,919 2.7%
normal normal intermediate 7 3.7% 38,423 3.8%
intermediate intermediate normal 6 3.1% 43,788 4.3%
ultrarapid normal normal 6 3.1% 24,435 2.4%
intermediate ultrarapid normal 5 2.6% 12,926 1.3%
normal intermediate intermediate 4 2.1% 15,811 1.6%
normal poor intermediate 2 1.0% 9,630 0.9%
poor normal normal 2 1.0% 13,693 1.4%
intermediate normal intermediate 1 0.5% 10,286 1.0%
intermediate intermediate intermediate 1 0.5% 4,306 0.4%
poor intermediate normal 1 0.5% 5,652 0.6%
ultrarapid poor normal 1 0.5% 5,995 0.6%
a Only includes patients with phenotype combinations that were observed in this sub-set of patients from the GUIDED trial
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to normal metabolizers is implied to increase the risk of therapy failure
(Hicks et al., 2015; Rudberg et al., 2008). As such, CPIC guidelines
recommend consideration of an alternative medication that is not pri-
marily metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers
(Hicks et al., 2015).
Although CPIC and FDA guidance for citalopram is based on
CYP2C19, consideration of the weighted, combined effect of all re-
levant phenotypes is critical to making appropriate clinical decisions.
For example, the majority of patients for whom citalopram and esci-
talopram was subject to significant gene-drug interactions with de-
creased metabolism according to the combinatorial pharmacogenomic
test were not CYP2C19 poor metabolizers. Still, there was a >50%
increase in citalopram concentration/dose ratios for these patients re-
lative to patients with no gene-drug interactions. Similarly, nearly a
third of all CYP2C19 intermediate metabolizers had significant gene-
drug interactions for citalopram and escitalopram according to the
combinatorial pharmacogenomic test due to the combined effects of
CYP2C19, CYP2D6, and CYP3A4, with a 59% increase in concentra-
tion/dose ratios. This shows that not only did the combinatorial phar-
macogenomic test accurately identify patients appropriate for a dose
reduction by existing CPIC and FDA standards, it also identified patients
who would not have been identified by CYP2C19 testing alone.
There is very little data directly equating medication blood levels
with safety or efficacy. However, Greden et al. demonstrated that pa-
tients in the GUIDED trial who remained on medications with sig-
nificant gene-drug interactions from baseline to week 8 had higher rates
of adverse events and poorer outcomes relative to those who changed to
medications with no/moderate gene-drug interactions (Greden et al.,
Fig. 2. Examining the Link Between Combined Phenotype and Citalopram and Escitalopram Blood Level Prediction. (A) The combinations of CYP2C19,
CYPD26, and CYP3A4 phenotypes are shown according to the combinatorial pharmacogenomic report category, which was based on the combined phenotype. (B)
Boxplot of the log-transformed concentration/dose ratios according to combinatorial pharmacogenomic report category. The median (thick horizontal line), in-
terquartile range (box), plus/minus 1.5xinterquartile range are shown, with outliers shown as individual dots.
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2019). Coupled with the data shown here regarding citalopram blood
levels when citalopram was subject to significant gene-drug interac-
tions, this provides indirect evidence >50% changes in medication
blood levels are associated with reduced safety and/or efficacy.
The data presented here show that, in addition to the combinatorial
pharmacogenomic test, CYP2C19 and CYP2D6 alone were individually
significant in predicting citalopram blood levels when using phenotypes
assigned by the combinatorial pharmacogenomic test. To directly
evaluate which method is superior, multivariate analyses that included
the individual genes and the combinatorial pharmacogenomic test were
performed and showed that only the combinatorial pharmacogenomic
test remained significant. This indicates that all variance in medication
blood levels explained by the individual genes is explained by the
pharmacogenomic test. The combinatorial pharmacogenomic test that
utilized a combined phenotype based on the weighted impact of
CYP2C19, CYP2D6, and CYP3A4 also provided additional, independent
information to explain variance in citalopram and escitalopram blood
levels.
The phenotypes observed in the GUIDED trial were largely re-
presentative of the full clinical testing cohort for the testing laboratory.
In the GUIDED cohort, 13 patients for whom citalopram or escitalopram
was in the “significant gene-drug interactions with reduced metabo-
lism” report category were not CYP2C19 poor metabolizers. However,
this translates to approximately 51,000 patients in the clinical testing
population. These patients would not have been identified as candi-
dates for dose modification based on CPIC guidance for citalopram
(Hicks et al., 2015). Importantly, citalopram blood levels in the
GUIDED cohort were >50% higher when citalopram was in the
“significant gene-drug interactions with reduced metabolism” report
category compared to when there were no gene-drug interactions.
Collectively, this highlights the clinical impact of utilizing the combi-
natorial pharmacogenomic test over CYP2C19 alone.
This study had some limitations. Blood samples and medication use
were assessed at the screening visit. As a result, patient outcomes could
not be correlated with blood-drug levels as predicted by combinatorial
pharmacogenomics versus individual genes. This prevents a direct
evaluation of whether the superior performance of the combinatorial
pharmacogenomic test in predicting citalopram and escitalopram blood
levels in this study directly results in improved patient outcomes re-
lative to CPIC assessments of individual genes. However, previous
studies have demonstrated improved outcomes with combinatorial
pharmacogenomic guided-care versus treatment as usual (Altar et al.,
2015; Greden et al., 2019; Hall-Flavin et al., 2013; Hall-Flavin et al.,
2012; Winner et al., 2013). The authors are not aware of any com-
parable studies for single-gene pharmacogenomic tests. Furthermore,
due to blood collection occurring at the screening visit, time since last
dose and concomitant medications use were not controlled for and
medication adherence was not collected. Patients were allowed to take
over-the-counter medications, psychotropic medications other than ci-
talopram, and prescription medications for other conditions. Some of
these medications may have had an impact on drug metabolism.
In summary, the ability to accurately predict medication blood le-
vels is an important measure of validity for pharmacogenomics testing.
Combinatorial pharmacogenomic testing that incorporates CYP2C19,
CYP2D6, and CYP3A4 was a superior predictor of citalopram and es-
citalopram blood levels compared to individual genes. The ability to
accurately predict clinically significant changes (≥50%) in medication
blood levels is critical to minimizing the risk that a medication will not
be safe or effective. With this combinatorial pharmacogenomic test,
more patients were identified as appropriate candidates for clinically
actionable dosing changes for citalopram and escitalopram from com-
prehensive and predictive information compared to single-gene testing
and CPIC classifications.
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